{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:59:27Z","timestamp":1791489567083,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":204,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101337","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:04:52Z","timestamp":1789646692000},"page":"101337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["FGF\/FGFR signaling in hepatocellular carcinoma: From molecular mechanisms to biomarker-guided therapy"],"prefix":"10.1016","volume":"49","author":[{"given":"qiangli","family":"jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghui","family":"jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10127","key":"10.1016\/j.ctarc.2026.101337_bib0001","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1016\/j.ctarc.2026.101337_bib0002","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","article-title":"Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101337_bib0003","first-page":"498","article-title":"Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians","volume":"75","author":"Moris","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70132","article-title":"Metabolic dysfunction-associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: a deadly triad","volume":"56","author":"Caturano","year":"2026","journal-title":"Eur. J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101337_bib0006","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13543784.2021.1948532","article-title":"Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"14","key":"10.1016\/j.ctarc.2026.101337_bib0007","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2217\/fon-2021-1623","article-title":"Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101337_bib0008","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14712598.2026.2642273","article-title":"Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer?","volume":"26","author":"Di Marco","year":"2026","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101337_bib0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101337_bib0011","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley. Interdiscip. Rev. Dev. Biol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101337_bib0012","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3390\/biom14121622","article-title":"Decoding FGF\/FGFR signaling: insights into biological functions and disease relevance","volume":"14","author":"Edirisinghe","year":"2024","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101337_bib0013","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3390\/ijms19071875","article-title":"FGF Family: from drug development to clinical application","volume":"19","author":"Hui","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0014","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101337_bib0015","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101337_bib0016","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101337_bib0017","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGF receptors: cancer biology and therapeutics","volume":"34","author":"Katoh","year":"2014","journal-title":"Med. Res. Rev."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101337_bib0018","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11684-019-0711-y","article-title":"The FGF metabolic axis","volume":"13","author":"Li","year":"2019","journal-title":"Front. Med."},{"issue":"40","key":"10.1016\/j.ctarc.2026.101337_bib0019","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208844119","article-title":"FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma","volume":"119","author":"Tao","year":"2022","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"key":"10.1016\/j.ctarc.2026.101337_bib0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-4598-11-14","article-title":"Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma","volume":"11","author":"Poh","year":"2012","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101337_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111545","article-title":"Isoform-specific inhibition of FGFR signaling achieved by a de-novo-designed mini-protein","volume":"41","author":"Park","year":"2022","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0022","first-page":"1","article-title":"Emerging roles of FGF signaling in hepatocellular carcinoma","volume":"5","author":"Zheng","year":"2016","journal-title":"Transl. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0023","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12575-025-00281-6","article-title":"Mechanisms of drug resistance in hepatocellular carcinoma","volume":"27","author":"Zou","year":"2025","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.ctarc.2026.101337_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104997","article-title":"Liver microenvironment and therapy resistance in hepatocellular carcinoma","volume":"216","author":"Rahi","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101337_bib0025","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/cancers13061360","article-title":"FGF\/FGFR signaling in hepatocellular carcinoma: from carcinogenesis to recent therapeutic intervention","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101337_bib0026","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/s41388-017-0017-y","article-title":"Ribosomal protein S15a promotes tumor angiogenesis via enhancing wnt\/\u03b2-catenin-induced FGF18 expression in hepatocellular carcinoma","volume":"37","author":"Guo","year":"2018","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101337_bib0027","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3892\/or.2017.5887","article-title":"FGF8 promotes cell proliferation and resistance to EGFR inhibitors via upregulation of EGFR in human hepatocellular carcinoma cells","volume":"38","author":"Pei","year":"2017","journal-title":"Oncol. Rep."},{"issue":"28","key":"10.1016\/j.ctarc.2026.101337_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202301166","article-title":"FGF9 Recruits \u03b2-catenin to increase hepatic ECM synthesis and promote NASH-driven HCC","volume":"10","author":"Zhang","year":"2023","journal-title":"Adv. Sci."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101337_bib0029","doi-asserted-by":"crossref","first-page":"13575","DOI":"10.18632\/oncotarget.6185","article-title":"FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3\u03b2\/\u03b2- catenin signaling cascade via FGFR4 activation","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.ctarc.2026.101337_bib0030","doi-asserted-by":"crossref","first-page":"9818","DOI":"10.3390\/ijms26199818","article-title":"Reactivation of the PI3K\/mTOR signaling pathway confers resistance to the FGFR4 inhibitor FGF401","volume":"26","author":"Huynh","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0031","doi-asserted-by":"crossref","first-page":"9137","DOI":"10.1038\/s41598-019-45537-w","article-title":"Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression","volume":"9","author":"Joo","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101337_bib0032","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.3892\/or.2013.2674","article-title":"Expression of angiogenic factors in hepatocarcinogenesis: identification by antibody arrays","volume":"30","author":"Nomura","year":"2013","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101337_bib0033","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.21873\/anticanres.13337","article-title":"Effect of Fibroblast Growth Factor-2 and its receptor gene polymorphisms on the survival of patients with Hepatitis B Virus-associated hepatocellular carcinoma","volume":"39","author":"Kim","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ctarc.2026.101337_bib0034","article-title":"Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance","volume":"15","author":"Zhang","year":"2025","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3892\/or.2013.2479","article-title":"Basic fibroblast growth factor upregulates survivin expression in hepatocellular carcinoma cells via a protein kinase B-dependent pathway","volume":"30","author":"Sun","year":"2013","journal-title":"Oncol. Rep."},{"issue":"61","key":"10.1016\/j.ctarc.2026.101337_bib0036","doi-asserted-by":"crossref","first-page":"104247","DOI":"10.18632\/oncotarget.22200","article-title":"Metformin reverses bFGF-induced epithelial-mesenchymal transition in HCC cells","volume":"8","author":"Chengye","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101337_bib0037","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41419-021-04410-3","article-title":"ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death. Dis."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101337_bib0038","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41419-021-04418-9","article-title":"Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death. Dis."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101337_bib0039","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000505695","article-title":"Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Liver. Cancer"},{"issue":"21","key":"10.1016\/j.ctarc.2026.101337_bib0040","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.3748\/wjg.v22.i21.5033","article-title":"(125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma","volume":"22","author":"Hu","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101337_bib0041","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/hep.24099","article-title":"Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis","volume":"53","author":"Gauglhofer","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ctarc.2026.101337_bib0042","article-title":"Advances of fibroblast growth factor\/receptor signaling pathway in hepatocellular carcinoma and its pharmacotherapeutic targets","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101337_bib0043","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.3892\/or.2017.5869","article-title":"Inhibition of the growth of hepatocellular carcinoma cells through fibroblast growth factor 18 suppressed by miR-139","volume":"38","author":"Yang","year":"2017","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101337_bib0044","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/liv.14505","article-title":"Interaction of FGF9 with FGFR3-IIIb\/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma","volume":"40","author":"Paur","year":"2020","journal-title":"Liver. Int."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0045","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1038\/s41598-020-61510-4","article-title":"Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma","volume":"10","author":"Seitz","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0046","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hep.26315","article-title":"MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor \u03b2 receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma","volume":"58","author":"Yang","year":"2013","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.ctarc.2026.101337_bib0047","doi-asserted-by":"crossref","first-page":"7823","DOI":"10.1007\/s00253-017-8468-1","article-title":"Expression and purification of an FGF9 fusion protein in E. coli, and the effects of the FGF9 subfamily on human hepatocellular carcinoma cell proliferation and migration","volume":"101","author":"Wang","year":"2017","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101337_bib0048","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101337_bib0049","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.ajpath.2021.04.014","article-title":"The role of fibroblast growth Factor 19 in hepatocellular carcinoma","volume":"191","author":"Chen","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ctarc.2026.101337_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115955","article-title":"FGF19\/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1","volume":"170","author":"Guo","year":"2024","journal-title":"Biomed. PharmacOther"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0051","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","article-title":"FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2","volume":"79","author":"Xie","year":"2023","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101337_bib0052","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s10620-013-2609-x","article-title":"Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma","volume":"58","author":"Hyeon","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0053","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1186\/s12885-019-6322-9","article-title":"Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma","volume":"19","author":"Maeda","year":"2019","journal-title":"BMC. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0054","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000488541","article-title":"Characterization of hepatocellular carcinoma patients with FGF19 amplification assessed by fluorescence in situ hybridization: a large cohort study","volume":"8","author":"Kang","year":"2019","journal-title":"Liver. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.onc.1210623","article-title":"Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models","volume":"27","author":"Desnoyers","year":"2008","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101337_bib0056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS. One"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101337_bib0057","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human phase I study of Fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0058","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-016-0478-9","article-title":"FGF19\/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib","volume":"36","author":"Gao","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101337_bib0059","article-title":"149MO Irpagratinib (ABSK-011) plus atezolizumab in first-line and immune checkpoint inhibitor-treated advanced hepatocellular carcinoma with FGF19 overexpression: updated results of the phase II ABSK-011-201 study","volume":"36","author":"Cheng","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101337_bib0060","unstructured":"Staff C N. FDA grants fast track designation to Irpagratinib in FGF19-overexpressed HCC [Z]. 2026."},{"key":"10.1016\/j.ctarc.2026.101337_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118642","article-title":"Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib","volume":"264","author":"Zhao","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0062","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227440","article-title":"Relation of fibroblast growth factor receptor 2 expression to hepatocellular carcinoma recurrence after liver resection","volume":"15","author":"Jun","year":"2020","journal-title":"PLoS. One"},{"issue":"34","key":"10.1016\/j.ctarc.2026.101337_bib0063","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.3748\/wjg.v11.i34.5266","article-title":"Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma","volume":"11","author":"Qiu","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101337_bib0064","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000179","article-title":"Tumor fibroblast growth factor receptor 4 level predicts the efficacy of Lenvatinib in patients with advanced hepatocellular carcinoma","volume":"11","author":"Yamauchi","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101337_bib0065","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2026.101337_bib0066","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-026-16098-9","article-title":"FGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade","volume":"26","author":"Wei","year":"2026","journal-title":"BMC. Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101337_bib0067","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s12072-021-10212-8","article-title":"Targeted inhibition of FGF19\/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma","volume":"15","author":"Tai","year":"2021","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0068","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/toxsci\/kfy031","article-title":"Bile acid sequestration by cholestyramine mitigates FGFR4 inhibition-induced ALT elevation","volume":"163","author":"Schadt","year":"2018","journal-title":"Toxicol. Sci."},{"issue":"28","key":"10.1016\/j.ctarc.2026.101337_bib0069","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101337_bib0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000486460","article-title":"A phase I\/randomized phase II study to evaluate the safety, pharmacokinetics, and efficacy of Nintedanib versus Sorafenib in Asian patients with advanced hepatocellular carcinoma","volume":"7","author":"Yen","year":"2018","journal-title":"Liver. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2019.02.015","article-title":"Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades","volume":"513","author":"Hoshi","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101337_bib0072","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1535-7163.MCT-18-1291","article-title":"FGF401, A first-In-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer","volume":"18","author":"Weiss","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101337_bib0073","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/2159-8290.CD-19-0367","article-title":"Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma","volume":"9","author":"Hatlen","year":"2019","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101337_bib0074","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdv591","article-title":"A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101337_bib0075","first-page":"2733","article-title":"Combined inhibition of FGFR4 and VEGFR signaling enhances efficacy in FGF19 driven hepatocellular carcinoma","volume":"12","author":"Zhao","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101337_bib0076","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12916-024-03356-5","article-title":"Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial","volume":"22","author":"Xu","year":"2024","journal-title":"BMC. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101337_bib0077","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1158\/1078-0432.CCR-20-3382","article-title":"ST6GAL1 Is a novel serum biomarker for Lenvatinib-susceptible FGF19-driven hepatocellular carcinoma","volume":"27","author":"Myojin","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:36:02Z","timestamp":1791488162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":77,"alternative-id":["S2468294226002480"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101337","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGF\/FGFR signaling in hepatocellular carcinoma: From molecular mechanisms to biomarker-guided therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101337"}}